Oslo University Hospital Licenses Colorectal Cancer Markers to OGT for Test Development | GenomeWeb

This article has been updated from a version posted Feb. 22 to include comments from an OGT executive.

Oxford Gene Technology has obtained an exclusive license to 12 "highly promising" colorectal cancer tissue biomarkers, the British array firm said this week.

The deal with Inven2, the technology transfer office at Oslo University Hospital and the University of Oslo, enables OGT to commercialize "any resulting test" developed using the markers as well as to sublicense the markers to other parties.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.